

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Currently Amended) A pharmaceutical composition for the treatment of ~~diseases~~ a disease related to gastric hyperacidity, ~~wherein it contains a combination of said composition comprising tenatoprazole and~~ one or more histamine H2-receptor antagonists ~~and tenatoprazole.~~

2. (Currently Amended) The composition according to claim 1, wherein the histamine H2-receptor antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine and nizatidine.

3. (Previously Presented) The composition according to claim 1, wherein the weight ratio between tenatoprazole and the histamine H2-receptor antagonist is between 1:30 and 1:2.

4. (Currently Amended) The composition according to claim 1, wherein ~~it contains~~ said composition comprises between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine H2-receptor antagonist.

5. (Original) The composition according to claim 1, wherein tenatoprazole is in the form of a potassium, magnesium, sodium or calcium salt.

6. (Currently Amended) The composition according to claim 1, wherein ~~it is presented~~ said composition is in a form for oral or parenteral administration.

7. (Cancelled)

8. (Cancelled)

9. (Previously Presented) The composition according to claim 2, wherein the weight ratio between tenatoprazole and the histamine H2-receptor antagonist is between 2:30 and 1:2.

10. (Currently Amended) The composition according to claim 2, wherein it ~~contains~~ said composition comprises between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine H2-receptor antagonist.

11. (Currently Amended) The composition according to claim 3, wherein it ~~contains~~ said composition comprises between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine H2-receptor antagonist.

12. (Currently Amended) The composition according to claim 2, wherein it ~~is presented~~ said composition is in a form for oral or parenteral administration.

13. (Currently Amended) The composition according to claim 3, wherein it ~~is presented~~ said composition is in a form for oral or parenteral administration.

14. (Currently Amended) The composition according to claim 4, wherein it ~~is presented~~ said composition is in a form for oral or parenteral administration.

15. (Currently Amended) The composition according to claim 5, wherein it ~~is presented~~ said composition is in a form for oral or parenteral administration.

16. (Currently Amended) A medicinal product useful for the treatment of ~~diseases~~ a disease related to gastric hyperacidity ~~comprised of~~ , said product comprising tenatoprazole and at least one histamine H2-receptor antagonist.

17. (Currently Amended) A method of treating ~~diseases relating~~ a disease related to gastric hyperacidity ~~which comprises~~ , said method comprising administering a medical

product ~~composed of~~ comprising tenatoprazole and at least one histamine H2-receptor antagonist.

18. (Currently Amended) The method of claim 17, wherein the ~~treatment~~ disease related to gastric hyperacidity is ~~for~~ gastric and duodenal ulcers[[,]] and symptoms and lesions related to gastroesophageal reflux.